Dispelling the myth: the use of renin-angiotensin blockade in atheromatous renovascular disease
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Many physicians retain reservations regarding the routine prescription of renin-angiotensin blockade (RAB) in patients with atheromatous renovascular disease (ARVD). Conversely, these patients are in most need of the cardio- and renal protection offered by RAB. This reservation is mostly because of fear of precipitating acute renal deterioration. We aimed to study whether RAB can be used safely in ARVD patients and whether it altered their outcome. METHODS: Prospective observational study of all ARVD patients presenting to our tertiary referral centre from 1999-2009. Data capture included usage and tolerability of RAB, and correlation with endpoints of cardiovascular events, dialysis or death. RESULTS: Six hundred and twenty-one subjects were available for analysis. Mean age (SD) of the cohort was 71.3 (8.8) years, median (interquartile range) follow-up 3.1 (2.1, 4.8), range 0.2-10.61 years. Seventy-four patients had an intolerance to RAB at study entry. When utilized prospectively, RAB was tolerated in 357 of 378 patients (92%), and this was even seen in 54/69 (78.3%) patients with bilateral>60% renal artery stenosis (RAS) or occlusion. Patients (4/21) who were intolerant of RAB during follow-up (and 12 retrospectively intolerant), underwent renal revascularization which facilitated safe use of these medications post-procedure. On multivariate time-adjusted analysis, patients receiving RAB were significantly less likely to die (P=0.02). CONCLUSION: RAB is well tolerated even in patients with bilateral severe RAS and reduced mortality in a large group of ARVD patients. We recommend all ARVD patients be considered for RAB therapy unless an absolute contra-indication exists. Intolerance of these agents due to renal dysfunction should be considered an emerging indication for renal revascularization to facilitate their re-introduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · Preventive Medicine · doi:10.1016/j.ypmed.2007.08.012 · Cited by 2,698
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2007) · Epidemiology · doi:10.1097/ede.0b013e3181577654 · Cited by 1,991
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f0580f · Cited by 1,837
Bakris, G. L., & Weir, M. R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.5.685 · Cited by 823 · cited 1×
“Interestingly, an inverse correlation has been described between the initial fall in GFR and the subsequent rate of renal functional decline over time [38].”
BackgroundShekelle, P. G., Rich, M. W., Morton, S. C., Atkinson, C. S. W., Tu, W., Maglione, M., Rhodes, S., Barrett, M., Fonarow, G. C., Greenberg, B., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00262-6 · Cited by 492
Remuzzi, G., Ruggenenti, P., Perna, A., Dimitrov, B. D., de Zeeuw, D., Hille, D. A., Shahinfar, S., Carides, G. W., & Brenner, B. M. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000146423.71226.0c · Cited by 123 · cited 5×
“A new CVE was defined as new onset angina, ischaemic heart disease (IHD), myocardial infarction, coronary or peripheral revascularization, hospitalization for congestive cardiac failure (CCF), peripheral vascular disease (PVD) or cerebrovascular accident/transient ischaemic attack in the study period.”
BackgroundInfluential
Research works printed but not linked: 36
- Kalra, 2010, Kidney international, 77, 37, 10.1038/ki.2009.406 · DOI
- 2007, Circulation, 115, 50, 10.1161/CIRCULATIONAHA.106.637751 · DOI
- Mailloux, 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation, 24, 622, 10.1016/S0272-6386(12)80223-X · DOI · Paper page
- Ihle, 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation, 27, 489, 10.1016/S0272-6386(96)90158-4 · DOI
- Casas, 2005, Lancet, 366, 2026, 10.1016/S0140-6736(05)67814-2 · DOI · Paper page
- Jafar, 2001, Annals of Internal Medicine, 135, 73, 10.7326/0003-4819-135-2-200107170-00007 · DOI · Paper page
- Williams, 2004, Journal of human hypertension, 18, 139, 10.1038/sj.jhh.1001683 · DOI · Paper page
- 2003, JAMA, 289, 2560, 10.1001/jama.289.19.2560 · DOI · Paper page
- 2005, Journal of the American Society of Nephrology, 16, 2746, 10.1681/ASN.2005010043 · DOI
- Harding, 1992, Journal of the American Society of Nephrology, 2, 1608, 10.1681/ASN.V2111608 · DOI · Paper page
- de Silva, 2007, The American journal of cardiology, 100, 273, 10.1016/j.amjcard.2007.02.098 · DOI
- Makanjuola, 1999, QJM, 92, 515, 10.1093/qjmed/92.9.515 · DOI
- The Heart Outcomes Prevention Evaluation Study Inv, 2000, New England Journal of Medicine, 342, 145, 10.1056/NEJM200001203420301 · DOI · Paper page
- 2006, Circulation, 114, 26, 10.1161/CIRCULATIONAHA.105.592733 · DOI · Paper page
- Goldsmith, 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation, 36, 837, 10.1053/ajkd.2000.17686 · DOI
- Burke, 2006, Journal of hypertension, 24, 1193, 10.1097/01.hjh.0000226211.95936.f5 · DOI · Paper page
- Franklin, 1985, The American journal of medicine, 79, 14, 10.1016/0002-9343(85)90075-0 · DOI
- Mann, 2001, Annals of Internal Medicine, 134, 629, 10.7326/0003-4819-134-8-200104170-00007 · DOI · Paper page
- Mann, 2002, American journal of cardiovascular drugs : drugs, devices, and other interventions, 2, 157, 10.2165/00129784-200202030-00003 · DOI
- 2007, Journal of the American College of Cardiology, 50, 2148, 10.1016/j.jacc.2007.08.029 · DOI
- Bart, 1997, The American journal of cardiology, 79, 1118, 10.1016/S0002-9149(97)00060-X · DOI
- 1996, QJM, 89, 145, 10.1093/qjmed/89.2.145 · DOI
- Suresh, 2000, Nephrology Dialysis Transplantation, 15, 631, 10.1093/ndt/15.5.631 · DOI
- Kalra, 2005, Kidney international, 68, 293, 10.1111/j.1523-1755.2005.00406.x · DOI · Paper page
- MacDowall, 1998, Lancet, 352, 13, 10.1016/S0140-6736(97)11060-1 · DOI · Paper page
- Missouris, 1994, The American journal of medicine, 96, 10, 10.1016/0002-9343(94)90109-0 · DOI
- 2008, Annals of Internal Medicine, 148, 30, 10.7326/0003-4819-148-1-200801010-00190 · DOI · Paper page
- Hricik, 1983, New England Journal of Medicine, 308, 373, 10.1056/NEJM198302173080706 · DOI · Paper page
- Ahmed, 2002, Journal of the American Geriatrics Society, 50, 1297, 10.1046/j.1532-5415.2002.50321.x · DOI
- van de Ven, 1998, Kidney international, 53, 986, 10.1111/j.1523-1755.1998.00840.x · DOI
- 2010, Clinical Journal of the American Society of Nephrology, 5, 623, 10.2215/CJN.07831109 · DOI
- 2008, QJM, 101, 519, 10.1093/qjmed/hcn039 · DOI
- 2005, Nephrology Dialysis Transplantation, 20, 1604, 10.1093/ndt/gfh865 · DOI · Paper page
- Peters, 1998, Kidney international, 54, 1570, 10.1046/j.1523-1755.1998.00164.x · DOI · Paper page
- Weinberg, 2004, American journal of nephrology, 24, 340, 10.1159/000078950 · DOI
- Khosla, 2006, American journal of therapeutics, 13, 306, 10.1097/00045391-200607000-00005 · DOI
Cited by
Aboyans, V., Ricco, J.-B., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T., Collet, J.-P., Czerny, M., De Carlo, M., Debus, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx095 · Cited by 3,293
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
“Although some studies indicated the tolerability and/or the efficacy of RA system inhibitors in RVHT patients with bilateral renal artery stenosis [1552, 1553], they have a risk to cause renal dysfunction [1554], and their safety has not been established.”
ResultCarey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153
Aboyans, V., Ricco, J.-B., Bartelink, M.-L. E. L., Björck, M., Brodmann, M., Cohnert, T., Collet, J.-P., Czerny, M., De Carlo, M., Debus, S., et al. (2018) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2017.07.018 · Cited by 963
Halliday, A., & Bax, J. J. (2018) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2018.03.004 · Cited by 651
Metadata
- Authors
- Chrysochou, C., Foley, R. N., Young, J. F., Khavandi, K., Cheung, C. M., & Kalra, P. A.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-10-12
- Volume
- 27
- Issue
- 4
- Pages
- 1403-1409
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2164686035
- Cited by
- 126
- References
- 8
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dispelling the myth: the use of renin-angiotensin blockade in atheromatous renovascular disease. https://app.cochat.ai/papers/10.1093/ndt/gfr496
- The paper
- Chrysochou, C., Foley, R. N., Young, J. F., Khavandi, K., Cheung, C. M., & Kalra, P. A. (2012). Dispelling the myth: the use of renin-angiotensin blockade in atheromatous renovascular disease. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfr496
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.